Critical Issues in Head and Neck Oncology : (Record no. 2743)
[ view plain ]
| 000 -Satzkennung | |
|---|---|
| Kontrollfeld mit fester Länge | 12339nam a22005053i 4500 |
| 001 - Kontrollnummer | |
| Kontrollfeld | EBC6636681 |
| 003 - Kontrollnummer Identifier | |
| Kontrollfeld | MiAaPQ |
| 005 - Datum und Zeit der letzten Transaktion | |
| Kontrollfeld | 20220324112744.0 |
| 006 - Datenelemente mit fester Länge - Weitere Materialmerkmale | |
| Kontrollfeld mit fester Länge | m o d | |
| 007 - Feld mit fester Länge zur physischen Beschreibung - Allgemeine Information | |
| Kontrollfeld mit fester Länge | cr cnu|||||||| |
| 008 - Feld mit fester Länge zur physischen Beschreibung - Allgemeine Angaben | |
| Kontrollfeld mit fester Länge | 220324s2021 xx o ||||0 eng d |
| 020 ## - Internationale Standardbuchnummer | |
| Internationale Standardbuchnummer | 9783030632342 |
| Nähere Angaben | (electronic bk.) |
| 020 ## - Internationale Standardbuchnummer | |
| Gelöschte/ungültige ISBN | 9783030632335 |
| 035 ## - Systemkontrollnummer | |
| System-Kontrollnummer | (MiAaPQ)EBC6636681 |
| 035 ## - Systemkontrollnummer | |
| System-Kontrollnummer | (Au-PeEL)EBL6636681 |
| 035 ## - Systemkontrollnummer | |
| System-Kontrollnummer | (OCoLC)1256238606 |
| 040 ## - Katalogisierungsquelle | |
| Original-Katalogisierungsstelle | MiAaPQ |
| Katalogisierungssprache | eng |
| Beschreibungsfestlegungen | rda |
| -- | pn |
| Übertragungsstelle | MiAaPQ |
| Bearbeitungsstelle | MiAaPQ |
| 050 #4 - Signatur der Library of Congress | |
| Notation | RC254-282 |
| 100 1# - Haupteintragung - Personenname | |
| Personenname | Vermorken, Jan B. |
| 245 10 - Titel | |
| Titel | Critical Issues in Head and Neck Oncology : |
| Zusatz zum Titel | Key Concepts from the Seventh THNO Meeting. |
| 264 #1 - Produktion, Veröffentlichung, Distribution, Herstellung und Urheberrechtsvermerk | |
| Herstellungs-, Veröffentlichungs- Vertriebs-, Erzeugungsort | Cham : |
| Produzent, Herausgeber, Distributor, Hersteller | Springer International Publishing AG, |
| Datum der Herstellung, der Veröffentlichung, des Vertriebs oder des Urheberschutzvermerks | 2021. |
| 264 #4 - Produktion, Veröffentlichung, Distribution, Herstellung und Urheberrechtsvermerk | |
| Datum der Herstellung, der Veröffentlichung, des Vertriebs oder des Urheberschutzvermerks | �2021. |
| 300 ## - Physische Beschreibung | |
| Umfang | 1 online resource (363 pages) |
| 336 ## - Inhaltstyp | |
| Inhaltstypterm | text |
| Inhaltstypcode | txt |
| Quelle | rdacontent |
| 337 ## - Medientyp | |
| Bezeichnung des Medientyps | computer |
| Medientypcode | c |
| Quelle | rdamedia |
| 338 ## - Datenträgertyp | |
| Datenträgertypbezeichnung | online resource |
| Datenträgertypcode | cr |
| Quelle | rdacarrier |
| 505 0# - Fußnote zu strukturierten Inhaltsangaben | |
| Fußnote zu strukturierten Inhaltsangaben | Intro -- Preface -- Contents -- Part I: Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) -- Chapter 1: Promising Biomarkers for Early Diagnosis and Prognosis Prediction -- Introduction -- Matrix Metalloproteinases -- Autophagy Biomarkers -- Intra-tumoural Immune Cells as Biomarkers -- References -- Chapter 2: Biomarkers for Hypoxia, HPVness, and Proliferation from Imaging Perspective -- Introduction -- Imaging Biomarkers for the Assessment of HPV-ness -- Imaging Biomarkers for Tumor Hypoxia -- Evaluation Treatment Response with RECIST 1.1 -- The Potential for Automatic Head and Neck Segmentation and Volumetric RECIST Assessment as Surrogate Imaging Marker for Tumor Proliferation -- Conclusions and Future Directions -- References -- Chapter 3: Mechanisms of Cetuximab Resistance and How to Overcome It -- Introduction -- The Epidermal Growth Factor Receptor -- Cetuximab as Anti-EGFR Targeting Agent -- Mechanisms of Cetuximab Resistance -- Altered Response Elicited at the Level of EGFR -- Molecular Alterations in Effectors Downstream of EGFR -- Cross-talk with Other Receptor Tyrosine Kinases -- Alterations in Proteins Outside the EGFR Pathway -- Epithelial-to-Mesenchymal Transition -- Hypoxia and Angiogenesis -- Strategies to Overcome Cetuximab Resistance -- Irreversible and Multiple HER Receptor Inhibition to Overcome Resistance -- Identification of Drug Resistance Mechanisms and Predictive Biomarkers -- Conclusion and Future Perspectives -- References -- Chapter 4: The Role of Liquid Biopsies for Monitoring Disease Evolution -- Introduction -- Liquid Biopsies for Cancer Screening and Disease Monitoring -- Early Detection of Virally Associated HNSCC Based on Plasma DNA -- Cell-free DNA Analysis in Non-virally Related HNSCC -- DNA Methylation Analysis for Cancer Screening -- Cell-Free Circulating Tumor DNA for Mutation Profiling. |
| 505 8# - Fußnote zu strukturierten Inhaltsangaben | |
| Fußnote zu strukturierten Inhaltsangaben | Concordance Between Liquid and Solid Tissue-Based Mutational Analysis -- ctDNA Versus CTCs: Which Is the Better Source for Mutation Analysis? -- Liquid Biopsies for Treatment Selection and the Analysis of Resistance Mechanisms -- Circulating Tumor Cells for Prognosis of Outcome in HNSCC -- Conclusions -- References -- Chapter 5: NK Cells in Immunotherapy: How Important Are They? -- Introduction -- NK Cells, Antitumor Effects and Antibody Dependent Cell Cytotoxicity -- Strategies to Enhance Antitumor NK Cell Function -- Reinforcement of NK Cell Activity -- Prevent NK Cell Inhibition -- Anti-PD-1 -- Anti NKG2A -- Anti KIR2 -- Anti TIM-3 -- Anti LAG-3 -- Anti-TIGIT -- Increase ADCC Through Engineering of Monoclonal Antibodies -- Improve NK Cells Trafficking and Homing in the Tumor -- CAR-NK -- Conclusions -- References -- Chapter 6: Biomarkers for Immune Modulatory Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) -- Background -- Potential Predictive Biomarkers for Immune Checkpoint Inhibitors -- PD-L1 -- Gene Expression Profiling -- Tumour Mutation Burden -- Combination of Tumour Mutation Burden and Gene Expression Profiling -- Multidimensional Quantitative IHC/IF -- Tissue Resident Memory (TRM) Cells -- Conclusion -- References -- Part II: Primary Disease -- Chapter 7: Novel Approaches in Surgical Management: How to Assess Surgical Margins -- Introduction -- Historical Background: The Concept of "Margin" -- Current Biological Rationale of Margins in Head and Neck Surgery -- Special Elements of Challenge in the Head and Neck Area -- Practical Determinants of Margin -- "Frailty" of Cutting Through Healthy Tissue -- Current Intraoperative Margin Evaluation -- Future Directions: "Know Your Enemy" -- Future Directions: Enhanced Tumor Visualization -- Future Directions: Augmented Mapping of the Surgical Bed -- Conclusions -- References. |
| 505 8# - Fußnote zu strukturierten Inhaltsangaben | |
| Fußnote zu strukturierten Inhaltsangaben | Chapter 8: The Surgical Approach to Elderly Patients with HNSCC -- Introduction -- Functional Physiological Age Related Issues with Impact on Selection for Surgical Treatment -- Assessment of Comorbidity for Surgical Treatment -- Age and Special Surgical Procedures -- Conclusion -- References -- Chapter 9: Contemporary Opportunities in Nonsurgical Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma -- Introduction -- Definition of LAHNSCC in HPV(+) HNC -- Trials on HPV(+) LAHNSCC -- Revisiting the Role of Cisplatin and Cetuximab in HPV(+) LAHNSCC -- Refining "Old Tools" for HPV(+) LAHNSCC: Dose, Fractionation, and Volumes -- Addressing Distant Metastasis Endpoint: Role of Induction Chemotherapy -- Quest for Additional Risk Stratification Parameters -- Emerging Role of Immunotherapy in HPV(+) LAHNSCC -- Research in HPV(−) LAHNSCC -- Window of Opportunity Trials Exploring Targeted Agents, Including immunotherapy -- Hypoxia Modification and Smoking Cessation -- Patients Unfit for Chemotherapy -- Conclusion -- References -- Chapter 10: High-Dose Three-Weekly or Low-Dose Weekly Cisplatin during Radiation, What to Prefer? -- Introduction -- High-Dose Three-Weekly Cisplatin -- Low-Dose Weekly Cisplatin -- High-Dose Three-Weekly Versus Low-Dose Weekly -- Level V Evidence -- Level IV Evidence -- Level III Evidence -- Level of Evidence II -- Level of Evidence I -- Immunotherapy Trials -- Concluding Remarks and Outlooks for the Future -- References -- Chapter 11: Where and when to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer -- Introduction -- Milestones in Systemic Therapies for Locoregionally Advanced HNSCC -- Comparison of the Practice Changing TPF Protocols (TAX 323/EORTC 24971 and TAX 324) -- When to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer -- For Larynx Preservation. |
| 505 8# - Fußnote zu strukturierten Inhaltsangaben | |
| Fußnote zu strukturierten Inhaltsangaben | For Treatment Intensification -- For Borderline Resectable or Unresectable Oral Cavity Cancer -- As a Selection Tool for RT Dose de-Escalation in HPV-Positive OPSCC -- Oligometastatic Disease -- Where to Use Induction Chemotherapy -- Conclusions -- References -- Chapter 12: Prognostic Role of p16/HPV in Non-oropharyngeal Head and Neck Squamous Cell Cancer (HNSCC) -- Introduction -- HPV Life Cycle -- Risk Factors for HPV(+) Non-OPC -- p16 as a Surrogate Biomarker for a Transcriptionally Active HPV Infection in Non-OPC -- p16/HPV as a Prognostic Factor in Non-OPC -- Conclusions -- References -- Chapter 13: Is there a Role for Neoadjuvant Targeted Therapy and Immunotherapy? -- Introduction -- Induction Therapy with Targeted Therapy and Immune Checkpoint Inhibitors -- Window of Opportunity Trials with Targeted Therapy and Immune Checkpoint Inhibitors -- Conclusion -- References -- Chapter 14: Is there a Role for Adjuvant Targeted and Immunotherapies in Patients with Locoregionally-Advanced Head and Neck Cancer? -- Introduction -- Adjuvant Post-Operative Chemoradiotherapy Improves Outcomes in LA-SCCHN -- Adjuvant Chemotherapy Is Not Effective in LA-SCCHN -- Epidermal Growth Factor Receptor-Targeted Therapies in LA-SCCHN -- Anti-EGFR Monoclonal Antibodies Are Not Used as Adjuvant Therapies for LA-SCCHN -- Small Tyrosine Kinase Inhibitors Are Not Effective Adjuvant Therapies in LA-SCCHN -- Immune Checkpoint Inhibitors as Adjuvant Therapies in LA-SCCHN -- Summary and Conclusions -- References -- Chapter 15: Optimal Supportive Measures during Primary Treatment -- Introduction -- Reasons to Implement Supportive Care during Curative Treatment in Head and Neck Cancer -- Multiple Interventions for Different Aspects of Support -- The Example of Mucositis: An Early and up-to-Date Supportive Care Intervention -- Conclusion -- References. |
| 505 8# - Fußnote zu strukturierten Inhaltsangaben | |
| Fußnote zu strukturierten Inhaltsangaben | Part III: Recurrent and/or Metastatic Disease -- Chapter 16: Salvage Surgery in Head and Neck Cancer -- Introduction -- Evolution of Salvage Surgery -- Tumor Factors -- Patient Factors -- Reconstructive Surgery after Resection for Salvage -- Arterial and Venous Options for Reconstruction in a Salvage Neck -- Venous Options for Reconstruction in a Salvage Neck -- Advanced Options for Reconstruction in a Salvage Neck -- Complications in Salvage Surgery -- Ideal Candidates -- Conclusion -- References -- Chapter 17: Re-Irradiation for Local Relapses or Second Primaries: When and how? -- Introduction -- When to re-Irradiate? -- Previous Toxicity and Patient-Related Considerations -- Treatment Volume and Recurrent Stage -- Time Interval since Initial Radiotherapy -- Anatomical Site -- Second Primary vs Recurrent Tumors -- Re-Irradiation after Salvage Surgery -- How to re-Irradiate? -- Re-Irradiation Dose -- Re-Irradiation Volume -- Concurrent Systemic Therapy -- Radiation Techniques -- Intensity-Modulated Radiotherapy (IMRT) -- Stereotactic Body Radiotherapy (SBRT) -- Proton Therapy -- Brachytherapy -- Toxicities of re-Irradiation -- References -- Chapter 18: New and Promising Targeted Therapies in First and Second-Line Settings -- Introduction -- EGFR Pathway -- Cetuximab -- Other ErbB Antibodies -- TKIs against ErbB -- Future Research into ErbB Targeting -- PI3K/AKT/mTOR Pathway -- Cell Cycle Regulation -- DNA Repair Inhibitors -- Antiangiogenesis -- RAS-RAF-MEK-ERK Pathway -- FGFR -- Neurotrophic Tyrosine Kinase Receptor Family -- Implications for Clinical Trial Design -- Conclusions -- References -- Chapter 19: Update of Immune Therapies in Recurrent/Metastatic Head and Neck Cancer -- Background: Prior to the Emergence of Immune Therapies -- Emergence of Immune Therapies in HNSCC -- Second-Line Randomised Trials of Immune Checkpoint Inhibitors. |
| 505 8# - Fußnote zu strukturierten Inhaltsangaben | |
| Fußnote zu strukturierten Inhaltsangaben | First-Line Randomised Trials of Immune Checkpoint Inhibitors. |
| 588 ## - Anmerkung zur Ausgabe, zum Teil oder zur Iteration, die/der als Grunlage für die Identifizierung der Ressource verwendet wird | |
| Anmerkung zur Ausgabe, zum Teil oder zur Iteration, die/der als Grunlage für die Identifizierung der Ressource verwendet wird | Description based on publisher supplied metadata and other sources. |
| 590 ## - Lokale Fußnote (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2022. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 655 #4 - Indexierungsterm - Genre/Form | |
| Genre/Form oder fokussierter Term | Electronic books. |
| 700 1# - Nebeneintragung - Personenname | |
| Personenname | Budach, Volker. |
| 700 1# - Nebeneintragung - Personenname | |
| Personenname | Leemans, C. Ren�e. |
| 700 1# - Nebeneintragung - Personenname | |
| Personenname | Machiels, Jean-Pascal. |
| 700 1# - Nebeneintragung - Personenname | |
| Personenname | Nicolai, Piero. |
| 700 1# - Nebeneintragung - Personenname | |
| Personenname | O'Sullivan, Brian. |
| 776 08 - Andere physische Form | |
| Verweisungsphrase | Print version: |
| Haupteintragung | Vermorken, Jan B. |
| Titel | Critical Issues in Head and Neck Oncology |
| Ort, Verlag und Erscheinungsjahr | Cham : Springer International Publishing AG,c2021 |
| Internationale Standardbuchnummer | 9783030632335 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Körperschafts- oder Gebietskörperschaftsname als Eintragungselement | ProQuest (Firm) |
| 856 40 - Elektronische Adresse und Zugriff | |
| URL | <a href="https://www.nbs.de/bibliothek/faq">https://www.nbs.de/bibliothek/faq</a> |
| OPAC-Notiz | Wie greife ich auf das E-Book zu? |
| 856 40 - Elektronische Adresse und Zugriff | |
| URL | <a href="https://ebookcentral.proquest.com/lib/nbsde/detail.action?docID=6636681">https://ebookcentral.proquest.com/lib/nbsde/detail.action?docID=6636681</a> |
| OPAC-Notiz | Click to View |
No items available.